How to Manage Post-Market Surveillance for Medical Devices in China

How to Manage Post-Market Surveillance for Medical Devices in China

China’s medical device post-market surveillance (PMS) system processed over 650,000 adverse event reports in 2024, reflecting a regulatory environment that is rapidly maturing — and becoming more demanding for foreign manufacturers. The National Medical Products Administration (NMPA) has progressively tightened post-market requirements since 2019, introducing mandatory adverse event monitoring systems, periodic risk assessments, and field inspections that now affect all Class II and III device registrants. For foreign manufacturers already marketing devices in China, compliance with PMS obligations is no longer a back-office function — it is a core regulatory requirement with direct consequences for product registration renewal, market access, and liability exposure.

Understanding the Regulatory Framework for Post-Market Surveillance in China

The legal foundation for medical device PMS in China is established by the Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, 2021) and its implementing rules. The NMPA requires all registrants to maintain a comprehensive PMS system covering adverse event monitoring, product safety updates, corrective action implementation, and periodic reporting. The regulatory framework draws heavily from the Global Harmonization Task Force (GHTF) model but incorporates China-specific requirements that foreign manufacturers must carefully navigate.

Key regulatory documents include the Measures for the Administration of Medical Device Adverse Event Monitoring and Re-evaluation (2023 revision), which expanded the scope of reportable events to include not only serious adverse events but also near-miss incidents and product quality defects that could potentially lead to adverse outcomes. The revised measures also introduced tiered reporting timelines: serious adverse events must be reported within 7 days, events requiring intervention within 20 days, and all other reportable incidents within 30 days.

Foreign manufacturers must establish a China-based PMS entity — either a local subsidiary, a liaison office, or a designated agent — that serves as the point of contact for NMPA communications and bears direct regulatory responsibility for PMS compliance. This entity must have qualified personnel who understand both the regulatory requirements and the Chinese language requirements for documentation.

Setting Up an Adverse Event Monitoring System Compliant with NMPA Requirements

The NMPA requires all registrants of Class II and III medical devices to maintain a real-time adverse event (AE) monitoring system integrated with the national Medical Device Adverse Event Monitoring Information System, a centralized platform operated by the Center for Medical Device Adverse Event Monitoring under the NMPA. The system must be capable of receiving, processing, and reporting AEs within the statutory timelines — 7 calendar days for serious AEs, 20 days for events requiring medical intervention, and 30 days for other reportable events.

Foreign manufacturers should implement an AE monitoring process that covers the complete product lifecycle, from initial patient contact through post-procedure follow-up. The monitoring system must include mechanisms for detecting, documenting, and assessing AEs from multiple sources: spontaneous reports from healthcare professionals and patients, literature surveillance for published case reports, post-market clinical follow-up studies, customer complaint data from distributors, and quality control data from manufacturing batches destined for China.

The monitoring system must be documented in a standard operating procedure (SOP) written in Chinese, approved by the local regulatory representative, and available for NMPA inspection. The SOP should define clear roles and responsibilities, escalation procedures, severity classification criteria aligned with NMPA definitions, and a corrective action protocol. An annual system audit by a qualified third party is strongly recommended.

1. Designate a China-based PMS officer with regulatory expertise and Chinese language proficiency
2. Establish a digital AE intake system that interfaces with the NMPA monitoring platform
3. Implement a 7-day serious AE escalation protocol with 24/7 reporting capability
4. Develop Chinese-language SMAF forms and reporting templates compliant with NMPA formats
5. Conduct annual simulated AE drills to validate system responsiveness and staff training

Preparing and Submitting Periodic Risk Assessment Reports

The Periodic Risk Assessment Report (PRAR) is a comprehensive document that registrants must submit to the NMPA annually for all registered medical devices. The PRAR summarizes the device’s safety profile over the reporting period, including adverse event data, risk-benefit analysis, corrective actions taken, and any changes to the device design or manufacturing that could affect safety or performance. The NMPA uses the PRAR as a primary input for determining whether to renew a device’s registration certificate, which is valid for five years.

The PRAR must include a quantitative analysis of adverse event rates compared to the previous reporting period, with statistical significance testing for any observed increases. For devices with cumulative AEs, the report must present a time-trend analysis identifying any emerging safety signals. The PRAR must also include a literature review of published safety data from Chinese and international journals, a summary of FSCAs issued during the period, and a corrective action plan with measurable timelines for implementation. Foreign manufacturers must translate all supporting documentation into Chinese and have the report reviewed and certified by the local regulatory representative before submission.

Managing Field Safety Corrective Actions (FSCAs) in China

When a medical device safety issue is identified through the AE monitoring system or other sources, the registrant must initiate a Field Safety Corrective Action (FSCA). FSCAs include product recalls, safety alerts, field modifications, software updates, and changes to labeling or instructions for use. The NMPA requires that FSCAs be reported within 72 hours of the registrant’s decision to take corrective action. The notification must include the device identification details, a description of the safety issue and its root cause, the affected batch or lot numbers, and the proposed corrective action plan.

The FSCA process in China has several distinctive features. The NMPA requires that all FSCAs be publicly announced through a government-designated channel — typically the provincial Medical Product Administration website — to ensure widespread dissemination to healthcare facilities and patients. For Class III and implantable devices, the manufacturer must also implement a patient notification system, which may include direct contact through healthcare providers or public service announcements. The NMPA has the authority to independently audit the FSCA implementation at the registrant’s facilities and can order expanded corrective actions if the proposed plan is deemed insufficient.

Preparing for NMPA On-Site Inspections of PMS Systems

The NMPA conducts on-site inspections of medical device registrants’ PMS systems as part of its routine regulatory oversight program. Approximately 15% of Class II and III device registrants are inspected annually, with higher rates for manufacturers of high-risk devices (cardiovascular implants, orthopedic devices, active implantable devices). The inspection teams typically consist of 2–4 inspectors from the NMPA or provincial Medical Product Administration and review the registrant’s PMS documentation for compliance with the applicable regulations and standards.

During a PMS inspection, NMPA inspectors evaluate the following areas: the completeness and accuracy of AE records, including timeliness of reporting; the quality and completeness of PRAR submissions; evidence of corrective action implementation and effectiveness; staff training records for PMS procedures; the adequacy of the local PMS entity’s resources and qualifications; and data integrity of the AE monitoring system. Inspectors may request access to the registrant’s electronic AE database, interview PMS staff, and cross-reference AE reports with distributor and hospital records. Foreign manufacturers should maintain all PMS records in both the original language and Chinese translation, with the Chinese version clearly marked as the regulatory-referenced copy.

Integrating PMS with Registration Renewal and Market Access Strategy

Post-market surveillance data has a direct and increasingly important impact on device registration renewal. The NMPA’s registration certificate renewal process now requires a comprehensive PMS dossier as a mandatory component of the application. Devices with an adverse event rate significantly higher than the industry benchmark may face renewal delays, additional data requirements, or — in extreme cases — certificate non-renewal. The NMPA publishes quarterly adverse event statistics benchmarked by device category, allowing manufacturers to track their performance relative to peers.

Foreign manufacturers should consider PMS not merely as a compliance obligation but as a strategic asset for maintaining and expanding their Chinese market access. A robust PMS system generates real-world evidence that can support labeling expansions, regulatory approvals for new indications, and competitive differentiation in hospital procurement processes. Manufacturers with well-documented PMS systems and favorable safety profiles may qualify for expedited NMPA review pathways for new device versions, reducing time-to-market by 6–12 months.

• Proactive PMS strategy: Invest in China-specific clinical data collection to support labeling claims and demonstrate local safety performance.
• Early warning integration: Connect your global AE database with the China AE monitoring system to ensure consistent signal detection.
• Distributor coordination: Train your China distributors on AE reporting obligations — they are often the first point of contact for hospital complaints.
• Regulatory intelligence: Subscribe to NMPA ADR monitoring newsletters and participate in industry working groups to anticipate regulatory changes.

Where to Go From Here

An effective post-market surveillance system is a regulatory necessity and a competitive advantage for foreign medical device manufacturers in China. Building the right infrastructure, processes, and relationships with NMPA takes time — but the commercial stakes in the Chinese market make this investment essential.

• Ready to act? Read a step-by-step guide to implementing an NMPA-compliant PMS system
• Still comparing? See a side-by-side comparison of PMS requirements in China, EU, and US
• Need numbers? Try an interactive PMS cost calculator for medical device registrants in China

How to Manage Post-Market Surveillance for Medical Devices in China — first published on China Gateway 360. Last updated: July 2026.